/
Company Overview We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience.
The business is unprofitable at the operating level (-512.91% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 23359.9% YoY with margins expanding 98505.3pp.
Negative free cash flow of -$277M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$71M
▲ +23359.9% YoY
Net Income (TTM)
-$361M
▼ -26.9% YoY
Op. Margin
-543.86%
▲ +98505.3pp YoY
ROIC
-48.23%
▲ +1.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$304M
▼ -18.9% YoY
Op. Cash Flow (TTM)
-$303M
▼ -19.0% YoY
Net Debt
-$711M
Net Cash Position
Cash & Equiv.
$762M
5Y CAGR: +132.2%
Continue Research